Literature DB >> 27862622

Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer.

Vinod Malik1, Ciaran Johnston2, Dermot O'Toole3, Julie Lucey4, Naoimh O'Farrell1, Zieta Claxton1, John V Reynolds1.   

Abstract

To determine the correlation between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) derived esophageal tumor parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV)] and endoscopic ultrasound (EUS) derived tumor parameters (T stage, N stage) and their prognostic implications. 150 consecutive patients with cancer of the esophagus or esophagogastric junction underwent staging PET-CT and staging EUS. PET-CT derived SUVmax and MTV of the primary tumor was recorded. EUS evaluated T and N stage. Relationships between parameters were investigated using the Mann-Whitney U tests, survival analysis performed using Kaplan-Meier and independent prognostic factors determined using Cox regression multivariate analysis. A significant difference in MTV was noted between EUS T1/T2 tumors (median 6.7 cm3) and EUS T3/T4 tumors (median 35.7 cm3; P < 0.0001). An MTV of <23.4 cm3 (P = 0.0001), SUVmax < 4.1 (P = 0014), EUS T stage (P < 0.0001), EUS N stage (P < 0.0001), and clinical stage (P < 0.0001) were all significantly associated with survival, with MTV <23.4 cm3 (P = 0.004), EUS T stage (P = 0.01), and EUS N stage (P = 0.01) significant in multivariate analysis. MTV, a volumetric parameter of PET-CT, has more prognostic importance than SUVmax and provides valuable prognostic information in esophageal and junctional cancer, along with EUS T and N stage. MTV provides complementary information to EUS and should be included in the staging of esophageal and junctional cancer.
© 2017 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  18F-FDG PET-CT; endoscopic ultrasound; esophageal cancer; staging

Mesh:

Substances:

Year:  2017        PMID: 27862622     DOI: 10.1111/dote.12505

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  5 in total

1.  Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit.

Authors:  Riccardo Giossi; Federica Carrara; Matteo Padroni; Maria Concetta Bilancio; Martina Mazzari; Silvia Enisci; Maria Silvia Romio; Gloria Boni; Federica Corrù; Veronica Andrea Fittipaldo; Irene Tramacere; Arianna Pani; Francesco Scaglione; Diego Fornasari
Journal:  Pain Ther       Date:  2022-09-21

2.  Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer.

Authors:  Alexander Herold; Christian Wassipaul; Michael Weber; Florian Lindenlaub; Sazan Rasul; Anton Stift; Judith Stift; Marius E Mayerhoefer; Marcus Hacker; Ahmed Ba-Ssalamah; Alexander R Haug; Dietmar Tamandl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-05       Impact factor: 10.057

3.  Relative tumor volume is a better independent prognostic factor in esophageal squamous cell carcinoma: Results of a retrospective study.

Authors:  Jun Lv; Huimin Gan; Wei Zhang; Linjiang Pan; Rensheng Wang; Yutao Qin
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

4.  Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer.

Authors:  Serena Baiocco; Bert-Ram Sah; Andrew Mallia; Christian Kelly-Morland; Radhouene Neji; J James Stirling; Sami Jeljeli; Alessandro Bevilacqua; Gary J R Cook; Vicky Goh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-27       Impact factor: 9.236

5.  18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

Authors:  Styliani Mantziari; Anastasia Pomoni; John O Prior; Michael Winiker; Pierre Allemann; Nicolas Demartines; Markus Schäfer
Journal:  BMC Med Imaging       Date:  2020-01-22       Impact factor: 1.930

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.